Amalgamated Bank Amylyx Pharmaceuticals, Inc. Transaction History

Amalgamated Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	SELL	$2.71 - $19.57 $14,845 - $107,204	-5,478 Reduced 76.04%	1,726 $5,000
Q4 2023 Feb 06, 2024	SELL	$12.07 - $18.46 $6,191 - $9,469	-513 Reduced 6.65%	7,204 $106,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $43,092 - $64,536	2,054 Added 36.27%	7,717 $166,000
Q1 2023 May 02, 2023	SELL	$27.71 - $40.93 $37,741 - $55,746	-1,362 Reduced 19.39%	5,663 $166,000
Q4 2022 Feb 10, 2023	BUY	$29.75 - $39.26 $66,848 - $88,217	2,247 Added 47.03%	7,025 $260,000
Q3 2022 Nov 09, 2022	BUY	$17.15 - $30.92 $55,806 - $100,613	3,254 Added 213.52%	4,778 $135,000
Q2 2022 Aug 15, 2022	SELL	$6.85 - $19.93 $1,637 - $4,763	-239 Reduced 13.56%	1,524 $29,000
Q1 2022 Jun 30, 2022	BUY	$12.85 - $32.9 $22,654 - $58,002	1,763 New	1,763 $23,000

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.